Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study.

H M Schenker; K Tascilar; L Konerth; M Sergeeva; J Prade; S Strobelt; A Kleyer; D Simon; L Mendez; M Hagen; V Schönau; Axel Hueber; J Roesch; A Dörfler; A Hess; G Schett; J Rech

doi:10.1016/j.conctc.2021.100770

Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study.

H M Schenker, K Tascilar, L Konerth, M Sergeeva, J Prade, S Strobelt, A Kleyer, D Simon, L Mendez, M Hagen, V Schönau, Axel Hueber (Co-author), J Roesch, A Dörfler, A Hess, G Schett, J Rech

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Original Article › peer-review

2 Citations (Web of Science)

Original language	English
Pages (from-to)	100770
Journal	CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS
Volume	22
DOIs	https://doi.org/10.1016/j.conctc.2021.100770
Publication status	Published - 2021

Keywords

HEALTH-ASSESSMENT QUESTIONNAIRE
ANTI-TNF THERAPY
PAIN
BLOCKADE
NEURONS
ALPHA

Access to Document

10.1016/j.conctc.2021.100770

Cite this

Schenker, H. M., Tascilar, K., Konerth, L., Sergeeva, M., Prade, J., Strobelt, S., Kleyer, A., Simon, D., Mendez, L., Hagen, M., Schönau, V., Hueber, A., Roesch, J., Dörfler, A., Hess, A., Schett, G., & Rech, J. (2021). Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 22, 100770. https://doi.org/10.1016/j.conctc.2021.100770

@article{e8101e59c0704f0888560892f10ae9e3,

title = "Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study.",

keywords = "HEALTH-ASSESSMENT QUESTIONNAIRE, ANTI-TNF THERAPY, PAIN, BLOCKADE, NEURONS, ALPHA",

author = "Schenker, {H M} and K Tascilar and L Konerth and M Sergeeva and J Prade and S Strobelt and A Kleyer and D Simon and L Mendez and M Hagen and V Sch{\"o}nau and Axel Hueber and J Roesch and A D{\"o}rfler and A Hess and G Schett and J Rech",

year = "2021",

doi = "10.1016/j.conctc.2021.100770",

language = "English",

volume = "22",

pages = "100770",

journal = "CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS",

issn = "2451-8654",

}

Schenker, HM, Tascilar, K, Konerth, L, Sergeeva, M, Prade, J, Strobelt, S, Kleyer, A, Simon, D, Mendez, L, Hagen, M, Schönau, V, Hueber, A, Roesch, J, Dörfler, A, Hess, A, Schett, G & Rech, J 2021, 'Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study.', CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, vol. 22, pp. 100770. https://doi.org/10.1016/j.conctc.2021.100770

Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study. / Schenker, H M; Tascilar, K; Konerth, L et al.
In: CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, Vol. 22, 2021, p. 100770.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study.

AU - Schenker, H M

AU - Tascilar, K

AU - Konerth, L

AU - Sergeeva, M

AU - Prade, J

AU - Strobelt, S

AU - Kleyer, A

AU - Simon, D

AU - Mendez, L

AU - Hagen, M

AU - Schönau, V

AU - Hueber, Axel

AU - Roesch, J

AU - Dörfler, A

AU - Hess, A

AU - Schett, G

AU - Rech, J

PY - 2021

Y1 - 2021

KW - HEALTH-ASSESSMENT QUESTIONNAIRE

KW - ANTI-TNF THERAPY

KW - PAIN

KW - BLOCKADE

KW - NEURONS

KW - ALPHA

U2 - 10.1016/j.conctc.2021.100770

DO - 10.1016/j.conctc.2021.100770

M3 - Original Article

C2 - 34041413

SN - 2451-8654

VL - 22

SP - 100770

JO - CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS

JF - CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS

ER -